"The population point prevalence of CFS is 0.1-0.9%, using restrictive (US)
criteria that exclude patients with psychiatric disorders, and 2.6% in primary care
using the Oxford criteria."
"
9.13 We emphasise the deleterious effects of unproven illness beliefs such as the
fear that any activity which causes an increase in fatigue is damaging - that ‘doing
too much’ causes permanent muscle damage and that CFS is irreversible or
untreatable.202 Research suggests that catastrophic or dysfunctional beliefs are
common in CFS patients and are related to disability.
203,204 Such inaccurate beliefs might fuel avoidance of activity, and then be
powerfully reinforced by the pain and fatigue which inevitably follow each
attempt to resume previous levels of activity."
"
9.23 We see no role for immunoglobulins, antihistamines or other immunotherapy.
There is no compelling evidence linking immune dysfunction with disability,224 and
no convincing evidence that any agent is effective.225-227 Antiviral agents are not
indicated.228 Experimental treatments such as immunotherapy should be given only
as part of controlled clinical trials. We see no role for vitamin or dietary supplementation"
"
We note positive evidence from well-planned trials and systematic reviews
supporting the use of antidepressants in such conditions as chronic pain,
premenstrual syndrome and fibromyalgia. We draw attention to the need for further
controlled clinical trials of antidepressants in non-depressed CFS patients before
making a recommendation."
"Whatever research is undertaken, the need for careful attention to methodology
is clear10 This includes the use of adequate case definitions, careful descriptions of
samples, the routine use of psychiatric screening instruments to allow stratification,
and the use of appropriate clinical outcome measures."
"
This report uses the term ‘CFS’ because there are recognised criteria for
definition. We urge others to do likewise. The term ME is widely used but not
precisely defined. We do not recommend use of this term in research or clinical
practice."
APPENDIX 1: Membership of the working group
Sir Richard Bayliss Consulting Physician, Westminister Hospital, London
Professor Leszek Borysiewicz Professor of Medicine, University of Wales College
of Medicine, Cardiff
Professor Robert Boyd Professor of Paediatrics, University of Manchester
Professor Francis Creed Professor of Community Psychiatry, University of Manchester
Dr Anthony David Reader in Neuropsychiatry, King’s College School of Medicine, London
Sir Anthony Dawson Consulting Physician, St Bartholomew’s Hospital, London
Professor Richard H T Edwards Professor of Medicine, University of Liverpool
Professor Elena Garralda, Professor of Child and Adolescent Psychiatry, St Mary’s Hospital Medical School, London
Mr John James Chief Executive, Kensington, Chelsea and Westminister Health Commissioning Agency
Dr Sean Lynch Senior Lecturer in Psychiatry, St James’s University Hospital,Leeds
Dr Anthony Pelosi Consultant Psychiatrist, Hairmyres Hospital, East Kilbride
Dr Tim Peto Consultant Physician in Infectious Diseases, John Radcliffe Hospital, Oxford
Dr Leone Ridsdale Senior Lecturer in General Practice, Guy’s & St Thomas’s
Medical and Dental School, London
Dr Margaret Thompson Consultant Child Psychiatrist, Southampton General Hospital
Dr Simon Wessely Reader in Psychological Medicine, King’s College School of Medicine, London
Dr Peter White Senior Lecturer in Psychiatry, St Bartholomew’s Hospital, London